

8. (new) The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 200% greater than the MTD for the unconjugated at least one anticancer compound.

9. (new) The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 300% greater than the MTD for the unconjugated at least one anticancer compound.

10. (new) The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 400% greater than the MTD for the unconjugated at least one anticancer compound.

N.E.
Please cancel claim 11.

Please add the following claim:

15. (new) The fatty acid-anticancer compound conjugate composition of claim 1, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

17. (amended) A method for treating a subject having an abnormal mammalian cell proliferative disorder, comprising administering to the subject a fatty acid-anticancer compound conjugate composition in an amount which is at least about 10% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound.

Please add the following claims:

24. (new) The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 200% greater than the MTD for the unconjugated at least one anticancer compound.

25. (new) The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 300% greater than the MTD for the unconjugated at least one anticancer compound.

26. (new) The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 400% greater than the MTD for the unconjugated at least one anticancer compound.

31. (new) The method of claim 17, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

33. (amended) A kit for administration of a fatty acid-anticancer compound conjugate composition to a subject, comprising
a container containing at least one fatty acid-anticancer compound conjugate, and
instructions for administering the at least one fatty acid-anticancer compound conjugate to subject in need of such treatment in an amount which is at least about 10% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound.

37. (new) The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 50% greater than the MTD for the unconjugated at least one anticancer compound.

39. (new) The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 100% greater than the MTD for the unconjugated at least one anticancer compound.

40. (new) The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 200% greater than the MTD for the unconjugated at least one anticancer compound.

41. (new) The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 300% greater than the MTD for the unconjugated at least one anticancer compound.

42. (new) The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 400% greater than the MTD for the unconjugated at least one anticancer compound.